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A B ST R AC T 
 
 
Over the past years, bone and adipose tissue have gained interest from 
researchers in the light of their secretory profiles, being able to produce 
active molecules, with the final effect of regulating energy homeostasis. 
Both adipocytes and osteoblasts originate in the pluripotent 
mesenchymal stem cell and this common origin has been proposed as 
the core of the fat-bone relationship. The central nervous system might 
be the third player in this association, capable of integrating signals. 
Numerous adipose tissue secreted factors that influence energy 
homeostasis and bone have been described: leptin, adiponectin, lipocalin 
2, and inflammatory cytokines (e.g. IL-1, IL-6 and TNF-α). Similarly, 
osteocalcin, the most abundant bone protein, has been shown to elicit 
numerous central and peripheral endocrine functions. In this paper, we 
provide a review of the current literature regarding the bone-adipose 
tissue-central nervous system axis and a brief description of the several 
underlying molecular mechanisms.   
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For many years, both bone and adipose tissue have been 
only considered as storage and support sites. However, in 
the more recent past, their secretory profiles have gained 
increasing attention, as it has been shown that both tissues 
produce molecules with autocrine, paracrine, and 
endocrine effects, with the final result of regulating energy 
homeostasis [1, 2]. The interaction between the skeleton 
and the adipose tissue had initially been studied with focus 
on mechanical loading and strain, but, as research has 
gained more insight into the physiology and pathology of 
both systems, molecular interconnections have started to 
become apparent. 
Both adipocytes and osteoblasts originate from the 
same precursor – the pluripotent mesenchymal stem cell 
(MSC) – and this common origin has been proposed as 
being at the core of the fat-bone relationship [3]. The 
central nervous system might be a third player in this 
relationship, capable of integrating signals. MSCs are 
regulated by endocrine, paracrine, and autocrine signals, 
and their preferential differentiation towards either 
adipocytes or osteoblasts might lead to imbalances and 
contribute to bone loss. However, the interactions are far 
from being straightforward. Many of the studied molecules 
have been found to have dual, opposing effects and/or 
effects that differ in vivo vs. in vitro. 
The adipose tissue secretes more than 50 hormones and 
signaling molecules, called adipokines, which are known 
to influence the physiological processes involved in 
glucose metabolism, immunity, and energy [4]. 
Adipokines have the ability to respond to signals from the 
central nervous system (CNS) and enable cross-
communication between various organs [5], allowing fat 
tissue to be involved in the complex control of bone 
biology.  
Similarly, in recent years, bone has emerged as an 
endocrine organ that secretes hormones and regulates 
energy metabolism, with osteocalcin (the most abundant 
bone protein) being shown to exert numerous endocrine 
functions, both centrally and peripherally [6]. Studies have 
revealed an association between bone metabolism, 
adipokines, inflammatory cytokines and brain, but these 
interactions are not fully explained.  
In this paper, we aim to provide a review of the current 
literature regarding the bone-adipose tissue-central 
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nervous system axis and a brief description of some 
underlying molecular mechanisms. 
Our review is based on a comprehensive search of the 
current literature in order to identify the relevant articles 
published until August 2020 in the PubMed database. The 
following terms were used in different combinations to 
generate the search: “adipose tissue”, “bone”, “brain”, 
“leptin”, “adiponectin”, “lipocalin 2”, “osteocalcin”, 
“fibroblast growth factor 23”, “inflammatory cytokines”. 
All identified articles were English language, full-text 
papers. We selected recent original articles, but some 
relevant reviews and older articles were also included. 
Discussions 
Mesenchymal stem cell – the same origin for adipocytes 
and osteoblasts 
Mesenchymal stem cells (MSCs), known as marrow 
stromal cells, are multipotent stem cells which can be 
found in most organs and tissues, such as fatty tissue, bone 
marrow, liver, kidney, lung, muscle, umbilical cord, and 
placenta [7]. Friedenstein et al. discovered mesenchymal 
stem cells in 1970 and described them as a non-
hematopoietic stem cell population in the bone marrow, 
spindle-shaped and “adherent” [8]; in the following years, 
the same research team described that non-hematopoietic 
stem cells had stem-like characteristics and maintained the 
potential to differentiate between bone, cartilage, and 
fibrous tissue in vivo [9, 10]. Caplan was the first to use the 
term “MSC” in 1991 to describe those cells that were able 
to differentiate between osteoblasts, chondroblasts, 
adipocytes, and myoblasts [11]. According to the 
International Society for Cellular Therapy, one of the most 
important criteria for a cell to be classified as mesenchymal 
stem cell (MSC) is the ability to differentiate between an 
osteoblast, chondroblast, or adipocyte in vitro [12]. Given 
the fact that adipocytes and osteoblasts share the same 
origin, the hypothesis that MSCs might play a role in the 
fat-bone relationship became apparent [13]. An alteration 
in MSC differentiation where adipocyte lineage formation 
is favored over the osteoblast lineage might lead to an 
imbalance in bone turnover and could contribute to bone 
loss. In vitro experiments have demonstrated that when 
adipogenesis is stimulated, osteoblast formation is 
inhibited, and reversely, adipogenesis is inhibited when the 
factors that favor osteoblastogenesis are dominant [14].  
The brain’s effects on the bone 
The CNS, especially the hypothalamus, has a major 
role in the control of energy homeostasis. The arcuate 
nucleus (ARC), the most important site in the 
hypothalamus, is involved in a number of neuroendocrine 
and physiological functions. ARC integrates the actions of 
metabolic mediators such as leptin, insulin, and ghrelin. 
Localized in the ARC, agouti-related protein (AgRP) 
neurons co-expressing neuropeptide Y (NPY) with a role 
in promoting food consumption and suppressing energy 
expenditure, also play a role in bone metabolism [15,16]. 
The anorexigenic neurons that co-express cocaine and 
amphetamine related transcript (CART) and 
proopiomelanocortin (POMC) are also involved in energy 
homeostasis. Cytokines and hormones are responsible for 
the central control of bone mass. One of them, leptin, is a 
modulator of NPY, can activate POMC neurons, and could 
affect bone resorption via central effects on CART [17–
19]. 
Adipose tissue as an endocrine organ 
The endocrine function of adipose tissue plays an 
important role in the crosstalk between organs and tissues. 
Adipokines present both pro-inflammatory and anti-
inflammatory properties. Signals from adipocytes that 
influence brain control of the bone mass have been 
identified, revealing the complex relationship between 
energy metabolism, its regulation, and bone homeostasis. 
Estrogens and vitamin D have both been studied 
extensively in the context of fat-bone crosstalk. Higher 
estrogen levels in obese individuals, owing to adipose 
aromatase expression, provide one simple molecular 
explanation for the positive relationship between excessive 
fat and bone metabolism; on the other hand, decreased 
vitamin D bioavailability (and secondary 
hyperparathyroidism), common in obese individuals, are 
consistent with the negative side of the relationship [20–
22]. 
 We now further discuss a number of factors secreted 
by adipocytes known to affect bone remodeling such as: 
leptin, adiponectin, pro-inflammatory cytokines 
(interleukins 1 and 6 (IL-1, IL-6) and tumor necrosis 
factor-alpha (TNF-α)).  
a. Leptin  
Leptin, derived from the Greek word “leptos” (meaning 
thin) and the product of the ob gene, is a small polypeptide 
hormone produced predominantly by the adipocyte (white 
adipose tissue [WAT]), which regulates weight, body 
metabolism, appetite, and reproductive function via the 
LEP receptor [23]. The mutation of the ob gene can cause 
obesity in mice; leptin deficiency in ob/ob mouse mutants 
leads to morbid obesity, hypothermia, hyperphagia and 
neuroendocrine abnormalities [24]. In addition, leptin 
receptor mutations causing leptin insensitivity lead to 
hyperphagia, morbid obesity, hypercorticism and other 
neuroendocrine abnormalities in mice (db/db mice) [25]. 
Leptin’s main site of action is the brain (at the 
hypothalamic level); intravenous leptin injections activate 
neurons in the arcuate (ARC), ventromedial, and 
dorsomedial hypothalamic nuclei [26].  The ARC is 
located in the third ventricle ventrally and contains neurons 
that produce cocaine and amphetamine modulates 
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transcript (CART), POMC, AgRP, neuropeptide Y (NPY), 
and gamma-aminobutyric acid (GABA), all of which are 
involved in energy balance regulation. POMC/CART-
secreting neurons are involved in catabolic pathways, 
while NPY/AgRP/GABA producing neurons have 
anabolic effects [27].  
Leptin inhibits the action of NPY and AgRP in the 
arcuate nucleus of hypothalamus, and increases the action 
of POMC and CART in order to decrease food intake 
[28,29].  
Leptin impacts bone metabolism through direct and 
indirect mechanisms, via peripheral and central pathways. 
In vitro data suggest a direct impact of leptin on bone cells, 
with a high level of leptin increasing osteoblast 
differentiation. In their study, Cornish et al. indicate a 
modest direct effect of leptin on bone cells resulting in a 
slight reduction of bone fragility. Leptin promotes growth 
in cultures of osteoblasts and chondrocytes [30]. Steppan 
et al. show an increase in bone size and bone mass after the 
in vivo administration of leptin to ob/ob mice [31]. These 
studies suggest that leptin has direct anabolic effects on 
osteoblasts. There is also evidence that leptin increases the 
osteoprotegerin levels and decreases the RANK-ligand 
levels in human marrow stromal cells; as well, it inhibits 
osteoclastogenesis in mouse bone marrow cultures [32]. 
These findings indicate a positive correlation between fat 
and bone.  
Tsuji et al. demonstrated a direct effect of leptin on 
bone growth through the fibroblast growth factor 23 (FGF-
23) [33]. Similar to adipocytes in peripheral body fat, 
adipocytes in the bone marrow also secrete leptin and these 
local effects contribute to leptin-bone complexity [34]. 
Conversely, the intra-cerebroventricular infusion of 
leptin in ob/ob and wild-type mice reduces bone mass, 
indicating  that, when acting via central mechanisms, leptin 
decreases bone mass [18]. Leptin’s involvement in 
osteoporosis pathophysiology has been hypothesized, as 
some authors have found that it correlates positively with 
bone mineral density (BMD) and bone mineral content 
(BMC) as indirect clinical indicators of osteoporosis 
[23,35,36]; however, there have also been studies that 
found a lack of correlation between leptin, BMD, and bone 
turnover markers [37,38].  
b. Adiponectin 
Adiponectin, a protein hormone produced by 
adipocytes, was first described in 1995 by Scherer and 
coworkers. It consists of 244 amino acids, with an N-
terminal signaling sequence, a hypervariable region, a 
collagenous domain, and a carboxy-terminal globular 
domain C1q like [39]. There are two main receptors for 
adiponectin, AdipoR1 and AdipoR2, which belong to a 
domain similar to G protein-coupled receptors (GCPR). 
Another receptor, T-cadherin, binds adiponectin in C2C12 
myoblasts and muscle, and it is important for adiponectin-
mediated cardioprotection in mice [40,41]. AdipoR1 
expression is ubiquitous, but the major expressing tissue is 
skeletal muscle, while AdipoR2 is predominantly 
expressed in the liver [42]. These receptors are also 
expressed in the brain. AdipoR1 and AdipoR2 are involved 
in glucose and lipid metabolism, mediating increased 
AMP-activated kinase (AMPK) and PPARs activities [43]. 
Due to the wide distribution of different receptors in the 
brain, adiponectin has a variety of central effects, such as 
thermogenesis regulation, energy expenditure, food intake, 
locomotor activity, cognition, anxiety, and mood [44]. 
Also, it is one of the adipokines with anti-inflammatory, 
antiatherogenic, antidiabetic, and cardioprotective effects 
[45].  Adiponectin is found in high concentrations in the 
blood, more specifically within a range of 5-30 ug/mL [46]. 
The adiponectin level is decreased in obese people 
compared to lean people [47]. Qi et al. have found that the 
concentration of adiponectin in the cerebrospinal fluid was 
1-4% of that in the serum and demonstrated that the intra-
cerebroventricular injection of adiponectin reduced body 
weight in normal and Lepob/ob mice without affecting 
food intake [48]. Cisternas et al., using cultured primary rat 
hippocampal neurons and mouse hippocampus slices, 
demonstrated a direct role of adiponectin and resistin in 
glucose metabolism in the hippocampus, through the 
increase of glucose uptake, ATIP production and 
glycolysis [49].  
Adiponectin might be a mediator of fat-bone 
relationship. Due to its anti-inflammatory effects, 
adiponectin suppresses TNF-α-induced nuclear factor kB 
(NF-kB) activation [50]. Receptors for adiponectin, 
AdipoR1 and AdipoR2, have been found on both osteoclast 
and osteoblast; most in vitro research suggests that 
adiponectin stimulates the proliferation and differentiation 
of the osteoblast, while inhibiting osteoclastogenesis 
[51,52].  These effects can be attributed to the involvement 
of adiponectin in RANK/RANKL/OPG axis. RANKL is a 
member of the tumor necrosis factor (TNF) family and 
influences the osteoclast activation responsible for bone 
resorption by binding to RANK. OPG (osteoprotegerin) 
secreted by osteoblasts and osteogenic stromal cells acts as 
a decoy receptor for RANKL and reduces the osteoclast 
differentiation, thereby inhibiting bone resorption [53]. 
Shinoda et al. analyzed the adiponectin effects on bone 
metabolism in adiponectin deficient and overexpressing 
transgenic mice; their study proposed opposing effects of 
adiponectin on bone formation, with circulating 
adiponectin directly inhibiting osteogenesis, but also 
having positive effects via the enhancement of insulin 
signaling and with locally produced adiponectin exerting 
positive effects via autocrine/paracrine pathways [54]. 
Clinical study results are contradictory when it comes 
to the association between adiponectin and BMD. Some 
studies show a negative correlation between adiponectin 
levels and bone mineral density (BMD) [55–57]. 
Regarding fractures, Barborur et al. reported that men with 
a high adiponectin level, had a higher risk of fracture, 
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independent of age, diabetes, body composition, and hip 
BMD [58], whereas other studies found no association 
between the risk of fracture and adiponectin level [59]. 
Further research is needed for a better understanding of the 
physiological role of adiponectin in bone biology and 
central function. 
c. Lipocalin 2 
Lipocalin-2 (LCN 2), known as neutrophil gelatinase-
associated lipocalin (NGAL) or 24p3, is a member of the 
lipocalin superfamily and is involved in the inflammatory 
process [60]. LCN2 is expressed especially in WAT [61], 
but other sources such as the kidney, liver, spleen, immune 
cells, bone marrow and chondrocytes have been identified. 
This adipokine is involved in a series of physiological and 
pathophysiological processes such as metabolic 
homeostasis, inflammation, the apoptosis of hematopoietic 
cells, the transportation of fatty acids, and metabolic 
disorders [62]. Circulating LCL2 concentrations were 
positively associated with adiposity, hyperglycemia, 
insulin resistance, and CRP levels [63]. The general view 
has been that LCN2 levels are mainly associated with 
excessive adiposity [61], but recent studies have 
challenged this view, revealing that LCN2 is expressed by 
osteoblasts at much higher levels (tenfold higher) than in 
WAT or other organs. Osteoblast-derived LCN2 crosses 
the blood-brain barrier and suppresses appetite after 
binding to the MC4R in paraventricular and ventromedial 
neurons of the hypothalamus with potency-like leptin. This 
osteoblast-derived ligand for MC4R represents one of the 
means through which bone coordinates energy balance, via 
central feedback [64]. The pathways in which LCN2 is 
involved are, at this moment, not completely understood. 
d. Inflammatory Cytokines 
Obesity is associated with a higher concentration of 
pro-inflammatory and anti-inflammatory cytokines, such 
as: IL-10, IL-6, IL-8, IL-1 receptor antagonist (IL-1Ra) and 
TNF-α. A various number of cytokines is known to 
influence bone cell functioning.   
Interleukin 1 (IL-1) 
Il-1 family has been associated with inflammation more 
than any other cytokine family. Ten members of the IL-1 
family have been identified: IL-1α, IL-1β, IL-1Ra, IL-18, 
IL-33, IL-36Ra, IL-36α, IL-36β, IL-36γ, IL-37, IL-38 [65]. 
The peripheral immune system, bone cells, glia, and neural 
cells in the central nervous system (CNS) are the 
expression sites of IL-1 [66]. In vitro and in vivo studies 
showed that IL-1 is a stimulator for bone resorption, with 
effects on osteoclasts – both direct and indirect, by 
stimulating RANK production. IL-18 inhibits 
osteoclastogenesis and it has variable effects on osteoblasts 
[67–71].  
Interleukin 6 (IL-6) 
IL-6 is a cytokine that plays different and opposing 
roles in cells and tissues. A high percentage of circulating 
IL-6 is derived from adipose tissue, but chondrocytes, 
osteoblasts, and skeletal and smooth muscle cells also 
produce it in variable amounts [72,73]. In his study, 
Wueest demonstrated that IL-6 induces the release of free 
fatty acid and leptin from adipocytes, therefore affecting 
glucose metabolism [73]. This interleukin also has a 
number of effects in the bone, influencing both osteoblast 
and osteoclast differentiation and activities [74]. IL-6 acts 
directly on osteoclast progenitors, suppressing their 
differentiation by inhibiting RANKL signaling pathways, 
with the final effect of decreasing bone resorption [75]. 
Yang et al. reported that IL-6 KO mice presented low bone 
mass and decreased osteoblast number; IL-6 appeared to 
play a role in the early stages of fracture healing (delayed 
in IL-6 KO mice) [76]. Because IL-6 acts on both 
peripheral and central nervous system, the mechanism is 
still not fully understood.   
Tumor necrosis factor alpha (TNF-α) 
TNF-α and TNF-β are two similar peptide members of 
the TNF superfamily. Adipocytes produce TNF-α, but 
macrophages in the stromal vascular fraction are the main 
source. TNF-α is also produced by monocytes, endothelial 
cells, astrocytes, lymphocytes, neutrophils, and smooth 
muscle cells. It is a pro-inflammatory cytokine and a potent 
lipid metabolism and insulin signaling receptor. TNF-α 
also exerts multiple actions on bone cells, such as inducing 
bone resorption (both in vitro and in vivo) by stimulating 
the proliferation and differentiation of osteoclasts 
precursors or activating mature osteoclasts; a direct 
inhibitory effect on osteoblasts has also been reported 
[77,78].  
Another interesting manner through which TNF-α and 
IL-1β impact bone health is through upregulation of 
osteoblast expression of 11β-HSD1, enhancing the 
negative effects of cortisol [79].  
Other interleukins 
The effects of other interleukins have also been 
described. For example, interleukin 4 inhibits osteoclast 
and osteoblast activity, interleukin 11 stimulates 
osteoclastogenesis and osteoblast differentiation, 
interleukin 8 stimulates bone resorption, interleukin 10 
inhibits osteoclastogenesis and osteoblastogenesis, 
interleukin 12 inhibits osteoclastogenesis, interleukin 13 
inhibits osteoclast and osteoblast activity, interleukin 15 
stimulates osteoclastogenesis, and interleukin 7, 17 have 
variable effects [69]. 
Bone as an endocrine organ 
a. Osteocalcin 
Osteocalcin (OC), also known as bone γ-carboxy 
glutamic acid protein, is the most abundant non-
collagenenous protein in bone and vitamin K-dependent 
protein. OC is an endocrine hormone and it regulates 
multiple organs, such as the brain, the pancreas, and the 
gonads. A low-level of OC has been reported in the 
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vascular smooth muscle cell, the brain, the kidney, the 
intestine, the bone marrow megakaryocytes, and the 
endothelial progenitor cells [80-82]. OC is produced by 
osteoblasts and it is a marker of bone formation, mostly 
involved in the process of mineralization. Its secretion 
by osteoblasts is controlled by the osteotesticular 
protein tyrosine phosphatase (OST-PTP) encoded by 
Esp (embryonic stem cell phosphatase) gene expressed 
in osteoblasts [81]. OC exists in two forms: 
undercarboxylated (uOC) and carboxylated (cOC). Esp-
deficient mice produce more undercarboxylated 
osteocalcin resulting in more insulin secretion, better 
insulin sensitivity, and hypoglycemia, while 
overexpression of Esp produces the opposite results. In 
their study, Lee et al. showed that uOC regulates glucose 
metabolism in mice [82] by increasing the expression of 
adiponectin by adipocytes. OC also increases B-cell 
proliferation and insulin production [83]. Ferron et al. 
(2012) tested the therapeutic potential of the intermittent 
administration of osteocalcin; daily injections with uOC 
were found to improve insulin resistance and glucose 
tolerance in obese mice on a high-fat diet [84]. A 
relationship between glucose, fat metabolism, and 
osteocalcin has also been described in humans [85]. 
Serum osteocalcin has been widely used to evaluate 
bone metabolism as a bone formation marker, but new 
evidence suggests that it might also represent an 
endocrine link between bone and energy metabolism, 
with central roles. The uncarboxylated form of OC can 
pass through the blood-brain barrier, accumulate in the 
brainstem, thalamus, and hypothalamus, and bind to 
neurons [86]. One study indicated that osteocalcin might 
function as a neuropeptide in the brain [87], while other 
studies revealed a central effect of OC through the 
stimulation of the neurotransmitter production [83]. A 
new study on mice and humans by Karsenty et al. (2019) 
has revealed that immediately after the brain recognizes 
a threatening situation, circulating osteocalcin levels 
quadruple very quickly (within 2 minutes in mice). In 
the absence of normal adrenal function, 
adrenalectomized rodents and adrenal-insufficient 
patients can develop a normal stress response; these 
findings showed that circulating levels of osteocalcin 
are enough to induce the acute stress response [88]. 
Based on these results, we can classify bone as a stress 
organ, and osteocalcin as a stress hormone. Further 
studies are necessary to unravel the link between brain 
and the glutamatergic neurons in bone and establish 
other inter-organ relationships.  
b. Fibroblast growth factor-23 (FGF23) 
FGF23, a member of the FGF family, is a glycoprotein 
produced predominantly in bone by osteoblasts and 
osteocytes with low levels in other tissues such as the 
ventrolateral thalamic nucleus of the brain [89]. FGF23 
regulates mineral metabolism by inhibiting urinary 
phosphate reabsorption and suppression of 1,25(OH)2D3 
production in the kidney. Klotho, localized in the proximal 
and distal tubules in the kidney, testis, sinoatrial node, and 
possibly bone, is a co-receptor for FGF23 [90–92]. The 
absence of Klotho or FGF23 leads to increased serum 
levels of 1,25 (OH)2D3, therefore Klotho-deficient mice 
and FGF23-deficient mice have been reported with 
hypercalcemia and hyperphosphatemia [93]. Murali et al. 
found that FGF23 controls osteopontin secretion indirectly 
by suppressing alkaline phosphatase transcription and 
phosphate production in osteoblastic cells in a Klotho-
independent manner [92].  
High levels of plasma FGF23 have been found in 
patients with chronic kidney disease, cardiovascular 
diseases, and inflammatory and metabolic diseases [94]. 
Inflammation proved to be a significant trigger of FGF23 
formation, and inflammatory cytokines are direct 
regulators of FGF23 in osteoblast; TNF-α plays a 
predominant role in FGF23 production [95,96]; Glosse et 
al. demonstrated that a high fat diet stimulates FGF23 
production through TNF-α formation in rodents [97]. 
Leptin administration increases serum FGF23 
concentration and decreases serum 1,25(OH)2D3 
concentration in leptin-deficient ob/ob mice to values 
observed in lean control mice [33].  
There is no clear evidence that FGF23 is produced by 
adipose tissue, but adipocytes express other members of 
the FGF family (FGF19, FGF21) that could be involved in 
energy regulation [98,99]. A number of clinical studies 
have described an independent association between higher 
FGF23 levels and adiposity (expressed through BMI and 
abdominal adipose tissue) in non-CKD population, 
suggesting that FGF23-related mechanisms might provide 
additional explanation for the skeletal changes seen in 
obesity [100, 101]. 
Highlights 
✓ Adipose tissue plays an important role in the crosstalk 
between organs and tissues. 
✓ Leptin impacts bone metabolism through direct and 
indirect mechanisms, via peripheral and central 
pathways. 
Conclusions 
Recent discoveries in the fields of molecular biology, 
enzymology, and physiology confirm the existence of a 
biocybernetic connection between fat and bone, modulated 
by the central nervous system. Understanding the 
interdependence between these systems is crucial in 
developing new drugs, treatment guidelines, and reducing 
the prevalence of metabolic and cardiovascular diseases in 
general. 
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Following the introduction of the term internal 
homeostasis by Claude Bernard in the 19th century, it was 
only a matter of time to subdivide and extrapolate this 
notion to smaller systems as our understanding of their 
functions and interactions to each other has increased. 
Studies on metabolic homeostasis identified leptin as a 
central modulator for the neuroendocrine axes and linked 
its levels to bone turnover. The hormones produced by the 
adipose tissues can stimulate adipogenesis and limit 
osteoblastogenesis in vitro, but the intricacy of the 
mechanisms seems to be insufficiently elucidated since 
there are uneven results in vivo. In this regard, further 
clarification of the inter- and intracellular signaling that 
governs the molecular crosstalk between bone and fat is 
needed. Furthermore, bone formation, resorption, and 
utilization of energy substrates are under subcortical 
control involving the hypothalamus, various cytokines, and 
multi-synaptic pathways. The complex relationship 
between these three different systems should be 
reconsidered using a unitary approach on energy and 
metabolic homeostasis in order to translate possible 
therapeutic implications into useful and safe future drugs.  
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